Semaglutide patent expiry is set to open a Rs 50 billion generic drug opportunity, boosting pharma revenues across India, regulated markets and emerging economies.
The Union Health Ministry is in discussions with state governments on the possibility of granting additional time to certain pharmaceutical manufacturers to comply with revised Good Manufacturing Practices (GMP) norms under Schedule M of the Drug...
Health ministry bans oral nimesulide above 100 mg for human use after DTAB and ICMR review, citing safety risks, second-line therapy use, and safer drug alternatives.
Dr. Reddy’s Labs receives a USFDA CRL for AVT03 denosumab biosimilar, citing manufacturing inspection issues, delaying approval in the key US biologics market.
Johnson & Johnson completes its $3.05 billion acquisition of Halda Therapeutics, strengthening its oncology pipeline with RIPTAC technology and expanding targeted cancer therapies.
Cupid has received in-principle approval from its Board of Directors to establish a new FMCG manufacturing facility in the Kingdom of Saudi Arabia (KSA), marking the company’s first manufacturing venture outside India.
Amneal Pharmaceuticals Inc. got an approval from the FDA for two denosumab biosimilars, growing their biosimilar offerings in the US.
The European Commission has approved Sanofi’s Wayrilz (rilzabrutinib), a new (novel) oral Bruton’s tyrosine kinase (BTK) inhibitor, as an additional treatment for patients with Immune Thrombocytopenia
The World Health Organization (WHO) has prequalified two rapid antigen test diagnostics (Ag-RDTs) for SARS-CoV-2 infections. This is historic, as Ag-RDTs are now prequalified for use for the first time.
Bristol Myers Squibb positions India as a growth engine, investing in AI-led pharma commercialization, pipeline expansion, and faster market adoption across oncology and cardiology.
.jpg)
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")